Innate Pharma (NASDAQ:IPHA – Get Free Report) released its earnings results on Wednesday. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.17, FiscalAI reports. The firm had revenue of $3.23 million during the quarter, compared to analysts’ expectations of $6.35 million.
Innate Pharma Stock Performance
Shares of NASDAQ:IPHA opened at $2.01 on Thursday. Innate Pharma has a 52-week low of $1.17 and a 52-week high of $2.71. The business has a fifty day moving average of $1.97 and a two-hundred day moving average of $1.74.
Analyst Upgrades and Downgrades
Several research analysts recently commented on the company. UBS Group reissued a “buy” rating on shares of Innate Pharma in a research note on Tuesday, August 11th. HC Wainwright lifted their target price on shares of Innate Pharma from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Weiss Ratings raised shares of Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 26th. Citigroup raised shares of Innate Pharma from a “buy” rating to an “outperform” rating in a research note on Tuesday, August 11th. Finally, BTIG Research boosted their price target on shares of Innate Pharma from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Innate Pharma currently has an average rating of “Moderate Buy” and a consensus target price of $6.67.
About Innate Pharma
Innate Pharma SA is a biotechnology company headquartered in Marseille, France, focused on developing immunotherapies for cancer. Founded in 1999, the company uses its expertise in the biology of natural killer cells and other components of the innate immune system to develop antibody-based treatments designed to help the immune system recognize and attack cancer cells.
Innate Pharma’s pipeline includes lacutamab, an investigational antibody targeting KIR3DL2 for certain forms of cutaneous T-cell lymphoma and other T-cell malignancies.
Further Reading
- Five stocks we like better than Innate Pharma
- IonQ and NVIDIA Just Cracked a Major Quantum Computing Bottleneck
- This Gold ETF Turns a Non-Yielding Asset Into Monthly Income—But There’s a Catch
- Analysts See Double-Digit Upside for These 3 Stocks
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
